Agency's top side not happy with slow change

Share this article:
FDA commissioner Margaret Hamburg and principal deputy commissioner Joshua Sharfstein say they are concerned by how long it takes to make changes in the agency. Their comments were reported in a New England Journal of Medicine assessment of their first year at the helm of FDA.
Hamburg told a February Institute of Medicine meeting that despite her past experiences working in government, she was struck by how long it takes to make a change at FDA. “You feel it differently at FDA —how long it takes to move things through the system,” she said. “The process of regulation does not allow you to respond in a timely way to emerging science or to other important emerging concerns.”
Sharfstein put it more bluntly: “I keep a list of things that I wish were moving faster and a list of things moving at just the right speed,” he said, “and there's nothing on the second list.”
The report said that Hamburg and Sharfstein have been trying to find ways to make FDA more nimble and proactive.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"